Global Biomarkers Market Forecast: Reaching $104.15 Billion By 2030

2025-12-02 05:08:25

(MENAFN- GetNews)

"By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030."The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period.

The global biomarkers market drug development, precision medicine, and companion diagnostics. Valued at US$58.07 billion in 2024, the market reached US$62.39 billion in 2025 and is projected to grow at a robust CAGR of 10.8% from 2025 to 2030, reaching US$104.15 billion by the end of the forecast period. This exponential rise underscores the critical role biomarkers play in enabling personalized treatment pathways, early disease detection, and clinical decision-making.

Market Growth Insights & Trends

Biomarkers have become essential tools in healthcare innovation. Their use in oncology, neurology, cardiology, and infectious diseases is reshaping diagnostics and therapeutics.

Market Size & Forecast: $62.39 billion in 2025 → $104.15 billion by 2030.
Growth Drivers: Increasing adoption of companion diagnostics and expansion of clinical trials leveraging biomarker data.

Download an Illustrative overview:

Key Market Drivers

Several forces are propelling the biomarkers market growth:

Rising Role of Companion Diagnostics – Biomarkers are central to tailoring therapies for individual patients, especially in oncology.
Advancements in Precision Medicine – The demand for patient-specific treatment approaches continues to expand.
Drug Development & Clinical Trials – Pharmaceutical companies increasingly rely on biomarkers to identify responders, reduce trial costs, and improve approval timelines.
Technological Innovations – Integration of AI, next-gen sequencing, and bioinformatics in biomarker research is accelerating discoveries.
Challenges & Opportunities

Despite strong growth, the biomarkers market faces obstacles:

Regulatory Hurdles – Complex approval processes can delay biomarker commercialization.
High R&D Costs – Developing biomarker assays requires substantial investment.
Data Standardization Issues – Harmonization of biomarker data across clinical settings remains limited.

However, opportunities abound in:

Liquid Biopsies – Non-invasive diagnostics are emerging as game changers.
Biomarker-Based Therapies – Accelerating demand in oncology, rare diseases, and autoimmune conditions.
Global Collaborations – Partnerships between pharma, biotech, and diagnostic companies are shaping the next wave of innovations.

Competitive Landscape

The biomarkers market is highly competitive, with global players investing heavily in R&D, partnerships, and acquisitions. Major companies include:

Roche Diagnostics
Thermo Fisher Scientific
Abbott Laboratories
Siemens Healthineers
Bio-Rad Laboratories
Qiagen N.V.

These companies are focusing on expanding biomarker assays, advancing companion diagnostics, and leveraging AI in biomarker discovery.

Request Sample Pages:

Future Outlook: Biomarkers Market 2030

Looking ahead, the biomarkers industry forecast points toward a future shaped by:

Wider adoption of digital biomarkers for remote monitoring and chronic disease management.
Next-generation sequencing (NGS) biomarkers integrated with clinical workflows.
Increased role in preventive healthcare with early detection and risk assessment models.
AI-powered biomarker discovery platforms reducing research timelines and costs.

By 2030, biomarkers will not just support diagnostics but become the backbone of global precision medicine.

Conclusion

The biomarkers market is on track to surpass US$104 billion by 2030, fueled by breakthroughs in drug development, diagnostics, and precision medicine. Companies that invest in innovation, partnerships, and data-driven biomarker research will be best positioned to capitalize on this rapidly evolving market.

For healthcare innovators, biotech leaders, and investors, now is the time to explore opportunities in the global biomarkers industry.

Get 10% Free Customization on this Report

Frequently Asked Questions (FAQs)

1. What is driving the growth of the biomarkers market? The key drivers include rising demand for precision medicine, growing use of companion diagnostics, and biomarker-based drug development.

2. How big is the biomarkers market expected to be by 2030? The market is projected to reach US$104.15 billion by 2030, growing at a CAGR of 10.8% from 2025.

3. Which industries benefit the most from biomarkers? Pharmaceuticals, biotechnology, diagnostics, and clinical research organizations (CROs) are the main beneficiaries.

4. Who are the major players in the biomarkers market? Key players include Roche, Thermo Fisher Scientific, Abbott, Siemens Healthineers, Bio-Rad, and Qiagen.

5. What role do biomarkers play in precision medicine? Biomarkers enable personalized treatment pathways, better patient stratification, and targeted therapy development.
MENAFN02122025003238003268ID1110424095

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.